SEOUL -- Investors cheered when Samsung Biologics announced Wednesday that its operating profit for the previous quarter had more than doubled on the year. Its share price accordingly shot up -- despite South Korea's financial regulators warning just a week before that biomedicine remains a risky investor bet.
That rare warning was prompted by a series of scandals and setbacks for an industry that was supposed to represent the next frontier for South Korea's economy.
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
to learn how you can update your cookie settings.